Neuberger Berman Group’s Allogene Therapeutics ALLO Stock Holding History

Neuberger Berman Group’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.8K	Buy	26,835 +12,010	+81%	+$26.4K	﹤0.01%	2281
2026 Q1	$36.2K	Buy	+14,825	New	+$29.7K	﹤0.01%	2126
2025 Q2	–	Sell	-16,621	Closed	-$24.3K	–	2053
2025 Q1	$24.3K	Buy	+16,621	New	+$31.3K	﹤0.01%	1933
2021 Q4	–	Sell	-8,085	Closed	-$208K	–	1907
2021 Q3	$208K	Hold	8,085	–	–	﹤0.01%	1685
2021 Q2	$211K	Sell	8,085 -8,161	-50%	-$233K	﹤0.01%	1700
2021 Q1	$574K	Sell	16,246 -555	-3%	-$18.7K	﹤0.01%	1451
2020 Q4	$431K	Buy	16,801 +891	+6%	+$29K	﹤0.01%	1429
2020 Q3	$613K	Buy	15,910 +1,650	+12%	+$62.2K	﹤0.01%	1313
2020 Q2	$610K	Buy	14,260 +660	+5%	+$23.9K	﹤0.01%	1243
2020 Q1	$265K	Buy	+13,600	New	+$324K	﹤0.01%	1368

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Neuberger Berman Group's ALLO Position: Q2 2026 in Review

Neuberger Berman Group increased its Allogene Therapeutics (ALLO) stake by 81% in Q2 2026, buying an estimated $26.4K and bringing the position to 26,835 shares worth $55.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

Neuberger Berman Group first reported a position in ALLO in Q1 2020 and has held it in 10 quarters since. The position peaked at $613K in Q3 2020. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Neuberger Berman Group held 26,835 shares of Allogene Therapeutics worth $55.8K as of Q2 2026.
Neuberger Berman Group bought 12,010 Allogene Therapeutics shares in Q2 2026, an estimated $26.4K.
Allogene Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2281 holding.
Neuberger Berman Group first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 10 quarters since.
Neuberger Berman Group's Allogene Therapeutics position peaked at $613K in Q3 2020.
210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.